Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s

Finding a way to maintain steady levels of medication is one of the biggest challenges in managing Parkinson’s. Most people are familiar with the "rollercoaster" effect of standard tablets, where symptoms return as the medicine wears off before the next dose. A promising new development from Serina Therapeutics aims to smooth out those peaks and troughs, and they have just reached a major milestone: the first person has officially enrolled in their Phase 1b clinical trial. This study is looking at a new way to deliver a well-known medication called apomorphine, potentially turning a difficult daily routine into a simple, once-a-week treatment. The Problem with the "On-Off" Cycle As the condition progresses, the brain’s ability to store dopamine diminishes. This leads to "off" periods—times when the medication isn't working effectively, and stiffness, tremors, or slow movement return. While apomorphine is an incredibly effective "rescue" drug for these moments, it is notoriously difficult to use. Currently, it often requires frequent injections or a bulky pump worn under the skin because the body breaks it down so quickly. Enter SER-252: The "Stealth" Delivery System The scientists at Serina have developed a clever solution using something called POZ technology. Instead of just injecting the medicine into the bloodstream where it disappears in minutes, they have attached the apomorphine to a special polymer chain. Think of it like a slow-release reservoir. Once injected under the skin, this polymer stays in place and slowly "snips off" tiny amounts of the medication, releasing them into the body at a constant, steady rate. The goal is to provide a continuous level of dopamine stimulation for an entire week from a single, small injection. What This Trial Means for the Future The "Phase 1b" trial is an important step. Its main purpose is to ensure the treatment is safe and to find the exact right dose that provides the best relief with the fewest side effects. Researchers will be looking closely at how well SER-252 reduces "off" time and whether it can help prevent the involuntary movements (dyskinesia) that often come with fluctuating medication levels. If successful, this could represent a massive shift in how we think about advanced care. Moving away from pills that need to be taken every few hours toward a weekly treatment would offer a level of freedom and consistency that is currently very hard to achieve. Staying Informed on the Journey Clinical trials are a long process, but the enrollment of the first person marks the official start of the clock for SER-252. It shows that the technology has moved out of the lab and is now being tested where it matters most—in the lives of people with the condition. While we wait for the data to come in, this development is a brilliant reminder that the "delivery" of our medicine is becoming just as advanced as the medicine itself.